Skip to main content

Nicholas J. Vogelzang, MD

Executive Medical Director, Associate Chair, Developmental Therapeutics and Genitourinary Committees, US Oncology Research, Houston, TX, and Comprehensive Cancer Centers of Nevada, Las Vegas

Authored Items
Review of US Comparative Economic Evidence for Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line VEGF Inhibitor Therapy
Michael K. Wong, MD, PhD, Nicholas J. Vogelzang, MD, Xufang Wang, MD, MBA, Maruit J. Chulikavit, Zhimei Liu, PhD
July 2013 Vol 6, No 5 in Business
Last modified: July 22, 2013